Early Effect of Intravitreal Faricimab on Hard Exudates in Diabetic Macular Oedema.

IF 4.2 3区医学 Q2 OPHTHALMOLOGY

Ophthalmology and Therapy Pub Date : 2026-09-01 Epub Date: 2026-08-08 DOI:10.1007/s40123-026-01464-4

Ameeta Kumar, Busaraben Gandhi, Arevik Ghulakhszian, Giovanni Ometto, Christiana Dinah

{"title":"Early Effect of Intravitreal Faricimab on Hard Exudates in Diabetic Macular Oedema.","authors":"Ameeta Kumar, Busaraben Gandhi, Arevik Ghulakhszian, Giovanni Ometto, Christiana Dinah","doi":"10.1007/s40123-026-01464-4","DOIUrl":null,"url":null,"abstract":"Introduction: Intravitreal faricimab is the first bispecific antibody to target vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2). In the study reported here, we examined the early effect of intravitreal faricimab on hard exudates (HEs) in patients with diabetic macular oedema (DMO).Methods: Consecutive patients who were initiated on faricimab for centre-involving DMO associated with HEs between August 2022 and July 2023 were reviewed. Areas of HE were confirmed on colour fundus photographs taken at initiation of therapy and at the 6-month follow-up. ImageJ software was used for semi-automated segmentation and measurement of the HE area within the Early Treatment Diabetic Retinopathy Study (ETDRS) grid. Demographic data, including age, gender and ethnicity, as well as best-corrected visual acuity (BCVA), central retinal thickness (CRT) and macular volume (MV) were recorded.Results: A total of 19 eyes from 16 patients were included in the study. Mean age of the cohort was 60.6 (range 49-71) years; ten eyes (53%) were treatment naïve. The median total HE area was reduced from 0.15 (interquartile range [IQR] 0.04-0.30) mm2 to 0.10 (IQR 0.07-0.24) mm2 by the 6-month follow-up. A greater reduction in total HE area was observed in treatment-naïve eyes (- 0.14 mm2) compared with previously treated eyes (+ 0.05 mm2), despite the former having a higher median baseline value (0.25 [IQR 0.15-0.47] mm2 vs 0.05 [IQR 0.04-0.15] mm2). Mean BCVA improved from LogMAR 0.26 ± 0.22 to 0.18 ± 0.19 (p < 0.05), while mean CRT and MV reduced from 413 ± 108 to 340 ± 95 μm (p < 0.001) and from 10.03 ± 1.41 to 9.20 ± 1.17 mm3 (p < 0.0001), respectively.Conclusion: Intravitreal faricimab may be associated with reduction of HE area in DMO within 6 months of initiation, with greater effects in treatment-naïve eyes. Further studies with longer follow-up are warranted to determine the durability of HE resolution and its comparison to intravitreal steroids and other anti-VEGF agents.","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"3145-3156"},"PeriodicalIF":4.2000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13518676/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40123-026-01464-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Intravitreal faricimab is the first bispecific antibody to target vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2). In the study reported here, we examined the early effect of intravitreal faricimab on hard exudates (HEs) in patients with diabetic macular oedema (DMO).

Methods: Consecutive patients who were initiated on faricimab for centre-involving DMO associated with HEs between August 2022 and July 2023 were reviewed. Areas of HE were confirmed on colour fundus photographs taken at initiation of therapy and at the 6-month follow-up. ImageJ software was used for semi-automated segmentation and measurement of the HE area within the Early Treatment Diabetic Retinopathy Study (ETDRS) grid. Demographic data, including age, gender and ethnicity, as well as best-corrected visual acuity (BCVA), central retinal thickness (CRT) and macular volume (MV) were recorded.

Results: A total of 19 eyes from 16 patients were included in the study. Mean age of the cohort was 60.6 (range 49-71) years; ten eyes (53%) were treatment naïve. The median total HE area was reduced from 0.15 (interquartile range [IQR] 0.04-0.30) mm² to 0.10 (IQR 0.07-0.24) mm² by the 6-month follow-up. A greater reduction in total HE area was observed in treatment-naïve eyes (- 0.14 mm²) compared with previously treated eyes (+ 0.05 mm²), despite the former having a higher median baseline value (0.25 [IQR 0.15-0.47] mm² vs 0.05 [IQR 0.04-0.15] mm²). Mean BCVA improved from LogMAR 0.26 ± 0.22 to 0.18 ± 0.19 (p < 0.05), while mean CRT and MV reduced from 413 ± 108 to 340 ± 95 μm (p < 0.001) and from 10.03 ± 1.41 to 9.20 ± 1.17 mm³ (p < 0.0001), respectively.

Conclusion: Intravitreal faricimab may be associated with reduction of HE area in DMO within 6 months of initiation, with greater effects in treatment-naïve eyes. Further studies with longer follow-up are warranted to determine the durability of HE resolution and its comparison to intravitreal steroids and other anti-VEGF agents.

查看原文本刊更多论文

玻璃体内法利西单抗治疗糖尿病黄斑水肿硬渗出的早期疗效。

玻璃体内法利昔单抗是首个针对血管内皮生长因子A （VEGF-A）和血管生成素-2 （ang2）的双特异性抗体。在这里报道的研究中，我们检查了玻璃体内法利西单抗对糖尿病黄斑水肿（DMO）患者硬渗出物（HEs）的早期影响。方法：回顾了2022年8月至2023年7月期间连续开始使用法昔单抗治疗中心涉及的he相关DMO的患者。在治疗开始时和6个月的随访中，通过彩色眼底照片确认HE区域。使用ImageJ软件对早期治疗糖尿病视网膜病变研究（ETDRS）网格中的HE区域进行半自动分割和测量。统计数据包括年龄、性别、种族、最佳矫正视力（BCVA）、视网膜中央厚度（CRT）和黄斑体积（MV）。结果：16例患者共19只眼纳入研究。该队列的平均年龄为60.6岁（49-71岁）；10只眼（53%）接受治疗naïve。在6个月的随访中，总HE面积中位数从0.15（四分位间距[IQR] 0.04-0.30） mm2减少到0.10 (IQR 0.07-0.24) mm2。与先前治疗的眼睛（+ 0.05 mm2）相比，treatment-naïve眼睛的HE总面积减少更大（- 0.14 mm2），尽管前者具有更高的中位基线值（0.25 [IQR 0.15-0.47] mm2 vs 0.05 [IQR 0.04-0.15] mm2）。平均BCVA从LogMAR 0.26±0.22改善到0.18±0.19 （p < 3）。结论：玻璃体内法利西单抗可在6个月内减少DMO的HE面积，对treatment-naïve眼的效果更大。进一步的研究需要更长时间的随访，以确定HE消退的持久性，并将其与玻璃体内类固醇和其他抗vegf药物进行比较。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ophthalmology and Therapy OPHTHALMOLOGY-

CiteScore

4.20

自引率

3.00%

发文量

157

审稿时长

6 weeks

期刊介绍： Aims and Scope Ophthalmology and Therapy is an international, open access, peer-reviewed (single-blind), and rapid publication journal. The scope of the journal is broad and will consider all scientifically sound research from preclinical, clinical (all phases), observational, real-world, and health outcomes research around the use of ophthalmological therapies, devices, and surgical techniques. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/series, trial protocols and short communications such as commentaries and editorials. Ophthalmology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. Rapid Publication The journal’s publication timelines aim for a rapid peer review of 2 weeks. If an article is accepted it will be published 3–4 weeks from acceptance. The rapid timelines are achieved through the combination of a dedicated in-house editorial team, who manage article workflow, and an extensive Editorial and Advisory Board who assist with peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid, efficient communication of the latest research and reviews, fostering the advancement of ophthalmic therapies. Open Access All articles published by Ophthalmology and Therapy are open access. Personal Service The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning authors will always have an editorial contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. Digital Features and Plain Language Summaries Ophthalmology and Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’. For examples of digital features please visit our showcase page https://springerhealthcare.com/expertise/publishing-digital-features/ Publication Fees Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of €5250/$6000/£4300. The journal will consider fee discounts and waivers for developing countries and this is decided on a case by case basis. Peer Review Process Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria. At least two extensive reviews are required to make the editorial decision, with the exception of some article types such as Commentaries, Editorials, and Letters which are generally reviewed by one member of the Editorial Board. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case-by-case basis and should be sent to the journal editor. Preprints We encourage posting of preprints of primary research manuscripts on preprint servers, authors’ or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Authors should disclose details of preprint posting during the submission process or at any other point during consideration in one of our journals. Once the manuscript is published, it is the author’s responsibility to ensure that the preprint record is updated with a publication reference, including the DOI and a URL link to the published version of the article on the journal website. Please follow the link for further information on preprint sharing: https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550 Copyright Ophthalmology and Therapy''s content is published open access under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0. Contact For more information about the journal, including pre-submission enquiries, please contact christopher.vautrinot@springer.com.